ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

1-メチル-4-フェニル-1,2,5,6-テトラヒドロピリジン

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

HCID 1388
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
28289-54-5
標準SMILES
CN1CC=C(c2ccccc2)CC1
InChIKey
PLRACCBDVIHHLZ-UHFFFAOYSA-N
分子式
C12H15N
平均分子量
173.25 g/mol
単同位体質量
173.12044948

概要

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4. It has a role as a neurotoxin. It is a member of methylpyridines, a tetrahydropyridine and a phenylpyridine.

名称と識別子

優先名称
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
IUPAC
1-methyl-4-phenyl-3,6-dihydro-2H-pyridine
現地名
1-メチル-4-フェニル-1,2,5,6-テトラヒドロピリジン
英語名
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
分子式
C12H15N
分子量
173.25

名称と別名

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine28289-54-5MPTPPYRIDINE, 1,2,3,6-TETRAHYDRO-1-METHYL-4-PHENYL-1,2,3,6-Tetrahydro-1-methyl-4-phenylpyridineDTXSID8040933N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine9P21XSP91PNSC-139654CHEBI:17963RefChem:76325DTXCID6020933
名称をさらに表示
1,2,5,6-テトラヒドロ-1-メチル-4-フェニルピリジン1-メチル-4-フェニル-1,2,3,6-テトラヒドロピリジン4-フェニル-1-メチル-1,2,5,6-テトラヒドロピリジン1,2,3,6-テトラヒドロ-1-メチル-4-フェニルピリジン1,2,3,6-テトラヒドロ-4-フェニル-1-メチルピリジン1-メチル-4-フェニル-1,2,5,6-テトラヒドロピリジンNSC 139654Naphthoic Acid Impurity 1111-Methyl-4-phenyl-1,2,3,6-tetrahydropyridin1,2,3,6-tetrahydro-1-methyl-4-phenyl-pyridin1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDRO-PYRIDINEN-METHYL-4-PHENYL-1,2,3,6-TETRAHYDRO-PYRIDINE
248-939-71-methyl-4-phenyl-3,6-dihydro-2H-pyridine1-METHYL-4-PHENYL-PIPERIDINE-3-ENCCRIS 2186HSDB 6942CHEMBL241721-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine1-Methyl-4-phenyl-1,2,3,6-tetrahydroxpyridine

物性

構造計算による物性補完中

XLogP
2.7
極性表面積
3.2 Ų
水素結合供与体数
0
水素結合受容体数
1
回転可能結合数
1
重原子数
13
形式電荷
0
複雑度
189

実験および物理化学的性質

Chemical ClassesNitrogen Compounds -> Pyridines
DrugsDEA NFLIS-Drug Category -> Narcotics
LogPlog Kow = 2.71 @ pH 7.5 (as MPP+)
Color/FormCrystals from heptane
Boiling Point85 to 90 °C @ 0.8 mm Hg
Melting Point40-42 °C
Vapor Pressure0.00945 [mmHg]
Physical DescriptionCrystals; [HSDB]

物理化学的性質

融点
36 °C · aprox. 36°C
沸点
128 · 128-132 °C12 mm Hg(lit.)
比重(密度)
1.001 · 1.001±0.06 g/cm3(Predicted)
貯蔵温度
Inert atmosphere,Room Temperature
溶解性
Chloroform (Slightly), Dichloromethane (Slightly), Ethyl Acetate (Slightly)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P301+P316, P308+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazards Summary · 1 件

The toxic effects of MPTP were discovered in 1982 when several injection drug users in San Jose, California developed frozen addict syndrome within a week of using MPPP contaminated with MPTP. The syndrome resembled idiopathic Parkinson disease, and patients showed some improvement after treatment with L-dopa. [Ford, p. 634-5] MPTP does not cause occupational parkinsonism, but it causes acute parkinsonism in humans and experimental animals after injection. The cumulative doses in animals are in the range of 1.5 to 410 mg/kg depending on the species. [See Reference #1}

Hazard Classes and CategoriesAcute Tox. 3 (100%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Treatment · 1 件

Because MPTP itself is not directly harmful, toxic effects of acute MPTP poisoning can be mitigated by the administration of monoamine oxidase inhibitors (MAOIs) such as selegiline. MAOIs prevent the metabolism of MPTP to MPP+ by inhibiting the action of MAO-B, minimizing toxicity and preventing neural death. (L1670)

化学と産業

薬理情報

Metabolism/Metabolites · 2 件

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has known human metabolites that include p-hydroxy-MPTP and 1-methyl-4-phenylpyridin-1-ium.

In the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme MAO-B of glial cells. (L1670)

MeSH Pharmacological Classification · 2 件

Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

用途と製造

Uses · 2 件

A contaminant produced during the synthesis of MPPP, a synthetic heroin; it causes irreversible parkinsonism in primates and is used in research laboratories; MPTP is converted to the toxic metabolite MPP+ in the brain where it selectively destroys cells in the substantia nigra. [Merck Index #6294]

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that causes permanent symptoms of Parkinson's disease by killing certain neurons in the substantia nigra of the brain. MPTP can be accidentally produced during the illicit manufacture of MPPP, and that is how its Parkinson-inducing effects were first discovered. MPTP is used to recreate and study the Parkinson's disease in experimental animal models.

Methods of ManufacturingPrepn as hydrochloride by Grignard reaction: A Ziering et al, J Org Chem 12, 894 (1947). Alternative prepn: CJ Schmidle, RC Mansfield, J Am Chem Soc 78, 425 (1956).
General Manufacturing InformationIdentification as impurity in "synthetic heroin".

応用分野

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a dopaminergic neurotoxin that reportedly causes a severe and irreversible Parkinsonian condition in humans and monkeys.

関連反応

9 件
反応記録を作成
HRID 225222 の反応式
HRID 225222反応物として
HRID 669905 の反応式
HRID 669905生成物として
HRID 1277525 の反応式
HRID 1277525反応物として
HRID 1568962 の反応式
HRID 1568962反応物として
HRID 1980093 の反応式
HRID 1980093反応物として
HRID 2134151 の反応式
HRID 2134151反応物として
HRID 2150391 の反応式
HRID 2150391反応物として
HRID 2163137 の反応式
HRID 2163137生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
28289-54-5
PubChem CID
1388
DTXSID
DTXSID8040933
ChEMBL
CHEMBL24172
ChEBI
CHEBI:17963
UNII
9P21XSP91P
EC Number
248-939-7
Nikkaji
J22.909A
酸解離定数(Pka)
8.66 · 8.66±0.40(Predicted)
外見
Solid
色
Pale Yellow to Light Yellow
Merck
13 · 13,6319
安定性
安定。強力な酸化剤とは相容れない。

化学的性質

化学的特性Light Yellow Solid

Adverse EffectsNeurotoxin - Parkinsonism
Toxicity Summary · 1 件

MPTP itself is not toxic, and as a lipophilic compound can cross the blood-brain barrier. Once inside the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme MAO-B of glial cells. MPP+ primarily kills dopamine-producing neurons in a part of the brain called the pars compacta of the substantia nigra. MPP+ interferes with complex I of the electron transport chain, a component of mitochondrial metabolism, which leads to cell death and causes the buildup of free radicals, toxic molecules that contribute further to cell destruction. (L1670)

Human Toxicity Excerpts · 1 件

chemical selective damage to cells in the substantia nigra occurs following human ingestion of MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine). ... Following iv injection of an illicit drug containing MPTP, humans developed chronic Parkinsonism, resulting from substantia nigra destruction.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Antidote and Emergency Treatment · 2 件

/SRP:/ Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

Toxicity DataLD50: 54 mg/kg (Subcutaneous, Mouse) (A2830)

安全データ

wgk
3
rtecs
UT8358900
ridadr
UN 2811 6.1/PG 2
毒性
Human toxicity originally discovered when it was an unexpected by-product from the illicit synthesis of a heroin substitute (i.e., meperidine analog). Currently used experimentally as the primary animal model for the study of Parkinson’s disease. MPTP is a neurotoxicant that is activated to 1-methyl-4-phenylpyridinium ion (MPP1) by the actions of monoamine oxidase B located in the mitochondria of brain astrocytes. The MPP1 is then transported into dopamine, and to a lesser extent, other monoaminergic neurons. Once inside these dopamine neurons in the substantia nigra, it destroys these neurons by mechanisms that may involve an oxidative cascade and/or inhibition of electron transport. Intoxication causes a parkinsonism syndrome almost identical in signs and symptoms to Parkinson’s disease, including rigidity, bradykinesia, tremor, and postural instability. In the event of known ingestion, immediate (but not delayed) administration of a monoamine oxidase inhibitor (especially one selective for MAO-B like deprenyl) and dopamine uptake inhibitor can be therapeutic.
risk_code
25-39/23/24/25
hazard_code
T
safety_code
45
hazard_class
6.1(b)
packing_group
III
有毒物質データの
28289-54-5(Hazardous Substances Data)
使用

補足説明

定義ChEBI: A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.